FP-1039

consists of the extracellular domain of FGF receptor 1c (FGFR1c) splice isoform fused to the Fc (crystallizable fragment) region of human immunoglobulin G; in Phase II trial (ClinicalTrials.gov identifier: NCT01244438) for endometrial cancers 5/2011

Also Known As:

Networked: 8 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	DeYoung, M Phillip: 3 articles (01/2020 - 06/2016)
2.	Baker-Neblett, Katherine: 2 articles (01/2020 - 10/2019)
3.	Dómine, Manuel: 2 articles (01/2020 - 10/2019)
4.	Mitrica, Ionel: 2 articles (01/2020 - 10/2019)
5.	Morgensztern, Daniel: 2 articles (01/2020 - 10/2019)
6.	Orlov, Sergey: 2 articles (01/2020 - 10/2019)
7.	Trigo, José: 2 articles (01/2020 - 10/2019)
8.	Vasquez, James: 2 articles (01/2020 - 10/2019)
9.	Wang, Xiaowei: 2 articles (01/2020 - 10/2019)
10.	Yan, Li: 2 articles (01/2020 - 10/2019)

Related Diseases

1.	Neoplasms (Cancer) 03/01/2016 - "Eligible patients with metastatic or locally advanced solid tumors for which standard treatments were ineffective were treated with weekly doses of FP-1039 for 4 weeks, followed by 2 weeks observation. " 06/28/2016 - "These data support the role of GSK3052230 in effectively targeting FGF-FGFR autocrine signaling in mesothelioma, demonstrate its impact on tumor growth and angiogenesis, and provide a rationale for the current clinical evaluation of this molecule in mesothelioma patients." 06/28/2016 - "GSK3052230 demonstrated antiproliferative activity across a panel of mesothelioma cell lines and inhibited growth of tumor xenografts in mice. " 05/09/2023 - "Using an siRNA assay, we demonstrated that FGF2-FGFR1 is the major anti-tumor target of FGFR1-Fc fusion the FGFR1-Fc fusion protein, which also significantly inhibited proliferation and invasion by NCI-H1703 cells via the FGF2-FGFR1 signaling pathway. " 03/27/2013 - "Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer."
2.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/01/2019 - "An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer."
3.	Malignant Mesothelioma 01/01/2020 - "Methods A multicenter, open-label, phase Ib study evaluated weekly GSK3052230 added to pemetrexed/cisplatin in patients with treatment-naive, unresectable malignant pleural mesothelioma. " 01/01/2020 - "A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma."
4.	Hyperphosphatemia 01/01/2020 - "Sequestering FGFs with GSK3052230 (FP-1039) blocks their ability to activate FGFRs while avoiding toxicities associated with small molecule inhibitors of FGFR, including hyperphosphatemia and retinal, nail, and skin toxicities. " 03/01/2016 - "In nonselected cancer patients with advanced disease, treatment with FP-1039 was well tolerated and toxicities associated with small molecule drugs that inhibit FGFR tyrosine kinases, including hyperphosphatemia, were not observed. "
5.	Mesothelioma 06/28/2016 - "These data support the role of GSK3052230 in effectively targeting FGF-FGFR autocrine signaling in mesothelioma, demonstrate its impact on tumor growth and angiogenesis, and provide a rationale for the current clinical evaluation of this molecule in mesothelioma patients." 06/28/2016 - "GSK3052230 demonstrated antiproliferative activity across a panel of mesothelioma cell lines and inhibited growth of tumor xenografts in mice. " 06/28/2016 - "Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230." 10/01/2014 - "Furthermore, RNAi-mediated silencing confirmed the requirement for FGFR1 in specific mesothelioma cells and sensitivity to the FGF ligand trap, FP-1039, validated the requirement for autocrine FGFs. "

Related Drugs and Biologics

1.	Ligands
2.	FP-1039
3.	Paclitaxel (Taxol)
4.	Carboplatin (JM8)
5.	Cisplatin (Platino)
6.	Docetaxel (Taxotere)
7.	Pemetrexed (MTA)
8.	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)
9.	Fibroblast Growth Factors (Fibroblast Growth Factor)
10.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)